Cognitive Behavioural Therapy Software for the Treatment of Depression in People With Multiple Sclerosis
Launched by UNIVERSITY OF SHEFFIELD · May 14, 2008
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18+
- • Diagnosis of MS confirmed by neurologist
- • Beck Depression Inventory-II score of at least 14 on two consecutive occasions
- • Not currently or within past three months receiving any treatment from a psychologist, psychotherapist or psychiatrist.
- • Willingness to be randomised to CCBT, at home or primary care facility or treatment as usual.
- Exclusion Criteria:
- • Unable to read or write English
- • Beck Depression Inventory score of at least 29 on two consecutive occasions
- • Active suicidal ideas
- * Current or life-time diagnosis of any of the following:
- • psychosis
- • organic mental disorder;
- • alcohol or drug dependency
- • Kurtzke Expanded Disability Status Scale (EDSS) score of 8.5 or above
- • Unable to use the CCBT package due to physical disability
- • Unable to use the CCBT package due to cognitive symptoms (mini-mental state of 20 below or if, in the opinion of the study psychologist, the individual would be unlikely to benefit from CCBT)
About University Of Sheffield
The University of Sheffield is a prestigious research institution located in the United Kingdom, renowned for its commitment to advancing medical science and improving patient outcomes through innovative clinical research. With a multidisciplinary approach, the university fosters collaboration among leading experts in various fields, facilitating cutting-edge studies that address critical health challenges. The University of Sheffield's clinical trials are designed to adhere to rigorous ethical standards and regulatory requirements, ensuring the reliability and integrity of their findings while contributing to the global body of medical knowledge. Through its dedication to excellence in research and education, the university aims to translate scientific discoveries into real-world applications that enhance health and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sheffield, South Yorkshire, United Kingdom
Patients applied
Trial Officials
Cindy L Cooper, PhD
Principal Investigator
University of Sheffield
Glenys D Parry, PhD
Study Chair
University of Sheffield
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials